MSB (ASX) Growing doubt on COVID-19 Application

Originally posted by Martin37: ↑

Thanks for clarifying Sore how you define the 'early stage' differently than the scientific and medical professions (and most rational people). Not surprising. So when you previously said stems only work in the early stage before you get really sick (most people would have rightly thought you were referring to Stage I - the viral replication phase), however you were in fact referring to the early stage of the pulmonary phase (Stage II). Talk about confusing your many followers old Sore. OK, glad we got that sorted.

You have previously said you need to treat prior to getting really sick, which you have now defined as before lung damage occurs (possibly early in Stage II), for the stems to work. In fact, a recent trial of stems for COVID-ARDS out of Israel from memory showed promising results here when infused early during the pulmonary phase (i.e. before intubation and presumably before any significant scarring of the lungs). Here we agree, I think there is scope for Rex-L to treat earlier in the COVID disease process as soon as abnormal chest imaging is confirmed. Of course I have a different view that this would be 'money well spent' in terms of improved long term health outcomes, faster time to hospital discharge, improved patient productivity post discharge etc. Maybe the (optimal) timing of the first dose will be investigated in any future trials?

Either way, if we are going for quick confirmation that Rex-L (particularly in combination with Dexa) decreases mortality and morbidity and decreases time to hospital discharge in under 65's, then fine by me. If this is the easiest path to an EUA then go for it!

However I strongly disagree with your suggestion that Rem-L needs to be administered ONLY before any significant lung symptomology arises (including scarring) for it to work. I say this because our initial trial enrolled patients with moderate to severe COVID-ARDS which would mean the majority would have progressed into the pink zone of the picture attached somewhat along the pulmonary phase pathway (mid-end Stage II) and into the hyperinflammation stage - aka cytokine storm - (Phase III); and positive results in terms of mortality reduction were reported in the under 65's (especially in combination with Dexa). In other words, I see saving lives (with no currently known other treatment option available, aside from Dexa, and the expensive supportive interventions of intubation and ECMO) during the latter stages of the deadly hyperinflammation (cytokine storm) stage of COVID-ARDS a success (works for me anyway). And I am sure if approved for moderate to severe COVID-ARDS patients experiencing hyperinflammation (cytokine storm) (where other options have largely failed) then the price tag will be more than justified by saving lives in a largely working age population and associated productivity improvements (economic benefits), shorter and cheaper hospital stays (economic benefits), and patient and societal benefits in terms of lives saved and expected improvements in Quality of Life (awaiting final 12 month data readouts).

Glad you clarified your definition of what you see as 'early phase' and 'really sick' so your followers can finally understand where you are coming from. May I suggest you change your script a little to reflect the more specific and agreed terminology, e.g. beginning of the pulmonary phase or Phase II, avoid scarring etc, to avoid confusion ( assuming it is not this type of confusion you desire to sprout ) if you feel the need to rehash your opinions again and again.

Thanks and enjoy your evening old bean.

Expand

Hi M37 , do you have a link or reference to the earlier MSC Covid Ards treatment in the Israeli trial?

My foggy Covid affected brain remembers Si mentioning earlier intervention was being looked at - perhaps it was the pneumonia stage?

Thankyou for your contributions

Reg

No.	Vol.	Price($)
4	64563	93.0¢

No.

Vol.

Price($)

64563

93.0¢

Price($)	Vol.	No.
94.0¢	204239	3

Price($)

Vol.

No.

94.0¢

204239

No.	Vol.	Price($)
4	64563	0.930
6	79973	0.925
13	254982	0.920
11	107275	0.915
4	115328	0.910

No.

Vol.

Price($)

64563

0.930

79973

0.925

254982

0.920

107275

0.915

115328

0.910

Price($)	Vol.	No.
0.940	204239	3
0.945	22942	2
0.950	91123	5
0.955	42425	1
0.960	61820	3

Price($)

Vol.

No.

0.940

204239

0.945

22942

0.950

91123

0.955

42425

0.960

61820

(20min delay)
Last 93.5¢		Change 0.020(2.19%)		Mkt cap ! $1.067B

Open	High	Low	Value	Volume
92.0¢	94.5¢	92.0¢	$1.622M	1.742M

Growing doubt on COVID-19 Application, page-1967

S&P 500 futures dip during non-deciding Trump-Harris Debate; bullish for energy

Lithium Universe 'dream team' ready to step into the demand-supply breach in Canada

HotCopper users liking Melbana Energy's news it's becoming an oil producer; shares jump +47%

UK-based Rightmove knocks back REA Group's acquisition proposal

Proteomics ends deal with Sonic Healthcare for US commercialisation of kidney disease test

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Growing doubt on COVID-19 Application, page-1967

Top Stories

S&P 500 futures dip during non-deciding Trump-Harris Debate; bullish for energy

Lithium Universe 'dream team' ready to step into the demand-supply breach in Canada

HotCopper users liking Melbana Energy's news it's becoming an oil producer; shares jump +47%

UK-based Rightmove knocks back REA Group's acquisition proposal

Proteomics ends deal with Sonic Healthcare for US commercialisation of kidney disease test

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News